|
|
|
|
|
|
|
|
Two New Executives Join VaxInnate Management Team
Vice Presidents of
Business Development and
Regulatory Affairs
to advance NJ biotech
company’s vaccine
development programs
|
CRANBURY,
NJ,
September
4,
2012
--
VaxInnate
Corporation
today
announced
the
expansion
of
its
executive
management
team
with
the
addition
of
Christine
Mayer
as
Vice
President
of
Business
Development
and
Katalin
Abraham
as
Vice
President
of
Regulatory
Affairs.
VaxInnate
is a
biotechnology
firm
pioneering
breakthrough
technology
for
the
development
of
novel
vaccines.
Mayer,
who
is
the
former
Senior
Vice
President
of
Business
Development
at
Biovail
Pharmaceuticals,
will
use
her
experience
in
collaborations
and
partnerships
to
help
VaxInnate
achieve
its
strategic
vision.
Abraham,
who
previously
served
as
Director
of
Regulatory
Affairs
at
GlaxoSmithKline
(GSK),
where
she
was
responsible
for
pandemic
and
adjuvanted
influenza
vaccines,
becomes
VaxInnate’s
primary
liaison
with
regulatory
agencies.
Both
will
play
integral
roles
in
advancing
the
development
of
VaxInnate’s
vaccines
for
three
key
infectious
diseases.
These
include
vaccines
for
seasonal
and
pandemic
flu;
dengue
fever,
a
growing
disease
that
affects
millions
globally;
and
Clostridium
difficile,
the
cause
of
increasing
disease
and
death,
primarily
among
elderly
populations
in
developed
countries.
“With
our
proprietary
vaccine
technology
and
the
funding
from
our
contract
with
the
U.S.
government
to
develop
flu
vaccines
in
place,
we
are
relying
on
the
skill
and
dedication
of
our
management
team
to
achieve
our
strategic
vision
for
VaxInnate,”
said
Wayne
Pisano,
President
and
CEO.
“Chris
and
Kati
join
VaxInnate
at a
most
opportune
time
and
we
are
confident
that
they
will
play
key
roles
in
helping
us
advance
our
novel
vaccine
programs
through
clinical
trials
to
the
marketplace.”
Prior
to
her
role
at
Biovail,
Mayer
served
in
senior
positions
at
sanofi
aventis
and
Johnson
&
Johnson.
She
received
a
bachelor’s
degree
from
Glassboro
State
College
and
a
master’s
degree
from
Rutgers
University.
Before
joining
GSK,
Abraham
held
senior
positions
at
Merck
&
Co,
Inc.
and
the
former
Centocor,
now
known
as
Janssen
Biotech,
Inc.
She
is a
graduate
of
the
University
of
Pennsylvania.
About
VaxInnate
VaxInnate
is a
privately-held
biotechnology
company
in
Cranbury,
NJ
that
is
pioneering
breakthrough
technology
for
use
in
developing
novel
and
proprietary
vaccines.
VaxInnate’s
vaccines
focus
on
infectious
diseases,
including
seasonal
and
pandemic
flu,
dengue,
malaria,
and
Clostridium
difficile.
VaxInnate’s
technology
has
the
potential
to
dramatically
improve
the
potency,
manufacturing
capacity
and
cost-effectiveness
of
vaccines.
In
2011,
Biomedical
Advanced
Research
and
Development
Authority
(BARDA),
part
of
the
U.S.
Department
of
Health
and
Human
Services
(HHS),
awarded
a
contract
to
VaxInnate
worth
up
to
$196
million
over
five
years
to
fund
the
development
of
seasonal
and
pandemic
flu
vaccines
using
recombinant
technology.
VaxInnate
has
already
generated
positive
Phase
I
and
Phase
II
clinical
data
for
its
flu
vaccines.
These
prototype
seasonal
and
pandemic
flu
vaccines
were
also
demonstrated
to
have
superior
potency
in
elderly
subjects.
For
more
information
about
VaxInnate,
please
visit
http://www.vaxinnate.com
###
Contact:
Janet
Skidmore
Office:
215-658-4915
Mobile:
215-429-2917
skidmorecomm@earthlink.net
. |
|
|
|
|
|
|
|
|
